<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82912">
  <stage>Registered</stage>
  <submitdate>19/06/2008</submitdate>
  <approvaldate>23/07/2008</approvaldate>
  <actrnumber>ACTRN12608000350325</actrnumber>
  <trial_identification>
    <studytitle>Antigen-sparing influenza vaccine study</studytitle>
    <scientifictitle>A randomised, controlled Phase 1/2 study in healthy adults to evaluate the safety and immunogenicity of an inulin-adjuvanted antigen-sparing seasonal trivalent inactivated influenza vaccine</scientifictitle>
    <utrn />
    <trialacronym>FLU004</trialacronym>
    <secondaryid>FLU004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>2008 seasonal trivalent inactivated influenza vaccine containing 15, 1.5 or 0.75 micrograms of haemagglutinin combined with polysaccharide adjuvant given once by intramuscular injection</interventions>
    <comparator>2008 seasonal trivalent inactivated influenza vaccine containing 45 micrograms of haemagglutinin and given once by intramuscular injection</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Immunogenicity as assessed by haemagglutinin inhibition assay on subject serum sample</outcome>
      <timepoint>1 month</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety assessment as assessed by incidence of subject reported adverse events (AE) including prespecified local AE (pain, tenderness, swelling, bruising, redness) and systemic AE (fever/chills, joint pain, headache, muscle ache, fatigue, nausea/vomiting, diarrhoea) plus reported serious adverse events</outcome>
      <timepoint>1 month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Persistence of immune protection as assessed by haemagglutinin inhibition assay on subject serum sample</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy male or female
Non-pregnant
If child bearing age, using contraception (barrier method, intrauterine device or oral contraception)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History of serious vaccine or egg allergy, Pregnant or lactating women, Concurrent immunosuppressive therapy, including corticosteroids (with the exception of topically applied/inhaled steroids), Participation in another clinical trial with an investigational agent within 14 days preceding initiation of treatment, History of Guillain-Barre syndrome, Any other serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/07/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vaxine pty Ltd</primarysponsorname>
    <primarysponsoraddress>Flinders Medical Centre
Adelaide 5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study in healthy adult subjects of an antigen-sparing influenza vaccine strategy incorporating an immune enhancing polysaccharide in the normal influenza vaccine</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Flinders Clinical Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre
Adelaide 5042</ethicaddress>
      <ethicapprovaldate>16/05/2008</ethicapprovaldate>
      <hrec>75/08</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor David Gordon</name>
      <address>Flinders Medical Centre
Adelaide 5042</address>
      <phone>0882044572</phone>
      <fax />
      <email>d.gordon@fmc.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor David Gordon</name>
      <address>Flinders Medical Centre
Adelaide 5042</address>
      <phone>0882044572</phone>
      <fax />
      <email>d.gordon@fmc.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Nikolai Petrovsky</name>
      <address>Flinders Medical Centre
Adelaide 5042</address>
      <phone>0882044572</phone>
      <fax>0882045987</fax>
      <email>nikolai.petrovsky@flinders.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>